Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.
Innate immune molecules such as lung collectins and serum pentraxins have evolved as important host defence proteins against Aspergillus fumigatus, a medically important opportunistic fungal pathogen. Mannan-binding lectin (MBL), an opsonin and lectin complement pathway activator, constitutes another vital player of innate immunity against several pathogenic organisms in the serum. Studies have reported significant binding of MBL to A. fumigatus; however, the protective role of MBL against A. fumigatus-mediated invasive disease remains elusive. Henceforth, we investigated the contribution of externally administered recombinant human (rh) MBL towards anti-fungal defence in invasive pulmonary aspergillosis (IPA) by in vivo and in vitro studies. In murine models of IPA with corticosteroid-induced immunosuppression, rhMBL-treated mice showed 80% survival compared to untreated IPA mice with no survivors. Treated IPA mice also showed a marked increase in tumour necrosis factor (TNF)-alpha and interleukin (IL)-1alpha and a significant decrease in pulmonary fungal hyphae and IL-10. In vitro, rhMBL-bound A. fumigatus conidia showed a dose-dependent increase in the deposition of C4b, the first product of the lectin pathway. There was an enhanced uptake of A. fumigatus conidia by the polymorphonuclear cells (PMNs) in the presence of rhMBL that increased further in the presence of MBL supplemented with MBL-deficient serum. However, an increase in the oxidative burst of PMNs and A. fumigatus killing were observed only when MBL was supplemented with MBL-deficient serum. The study suggests a therapeutic role of ex vivo-administered MBL in host defence against aspergillosis, possibly through MBL-mediated complement activation and other protective mechanisms aimed both directly at the pathogen, and indirectly through modulation of the host inflammatory responses.
Kaur
S
S
Molecular Biochemistry and Diagnostics, Institute of Genomics and Integrative Biology, Mall Road, Delhi, India.
Gupta
V K
VK
Thiel
S
S
Sarma
P U
PU
Madan
T
T
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D002478:Cells, Cultured; D050716:Complement C4b-Binding Protein / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008172:Lung Diseases, Fungal / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D037601:Mannose-Binding Lectin / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use; D016897:Respiratory Burst; D016019:Survival Analysis
D000935:Antifungal Agents; D050716:Complement C4b-Binding Protein; D016207:Cytokines; D037601:Mannose-Binding Lectin; D011994:Recombinant Proteins